NeoManna

Company Overview

Snapshot

Founded in January 2022 by Amir Barzilay, NeoManna operates with 1–10 employees. The company has secured funding across one round from AgChimedes Group to develop novel antimicrobial and anti-inflammatory products for animal health.

Business overview

NeoManna specializes in developing, manufacturing, and selling natural antimicrobial and anti-inflammatory products to combat antibiotic overuse in livestock, aquaculture, and companion animals. The company leverages an innovative CAPEX-free model and R&D in Black Soldier Fly (BSF) originated bioactives. These bioactives are incorporated into liquid and solid animal nutrition, aiming to reduce production costs, improve EBITDA, and safeguard the global food value chain. NeoManna operates within the Agriculture & Food Technologies sector, serving markets across Western Europe, Asia, South America, Israel, Central America, and North America.

Company Intelligence Q&A

When was NeoManna founded?

NeoManna was founded in January 2022.

Who is a co-founder of NeoManna?

Amir Barzilay is a co-founder and CEO of NeoManna.

What is NeoManna's primary focus?

NeoManna focuses on addressing global challenges related to Anti-Microbial Resistance (AMR) by developing natural antimicrobial and anti-inflammatory products for animal health.

What is NeoManna's core technology?

NeoManna's core technology involves groundbreaking R&D in Black Soldier Fly (BSF) originated bioactives, which are used in their animal nutrition products.

Which markets does NeoManna target?

NeoManna targets geomarkets including Western Europe, Asia, South America, Israel, Central America, and North America.